Overview

Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma

Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This research study is testing the "chemo-switch" strategy in melanoma, using biochemotherapy initially to shrink tumors and then switching to daily low-dose chemotherapy (temozolomide) together with sorafenib. The purpose of this study is to find out what effects (good and bad) biochemotherapy followed by temozolomide plus sorafenib have on melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborator:
Bayer
Treatments:
Dacarbazine
Sorafenib
Temozolomide